AR109254A1 - Composición farmacéutica que comprende bencidamina - Google Patents
Composición farmacéutica que comprende bencidaminaInfo
- Publication number
- AR109254A1 AR109254A1 ARP170101851A ARP170101851A AR109254A1 AR 109254 A1 AR109254 A1 AR 109254A1 AR P170101851 A ARP170101851 A AR P170101851A AR P170101851 A ARP170101851 A AR P170101851A AR 109254 A1 AR109254 A1 AR 109254A1
- Authority
- AR
- Argentina
- Prior art keywords
- amount
- pharmaceutical composition
- benzydamine
- fatty acid
- ester
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición farmacéutica en crema, crema-gel, o gel, que comprende bencidamina, que tiene tolerabilidad y eficacia mejoradas para la .prevención y tratamiento de enfermedades inflamatorias y/o infecciosas localizadas principalmente en el área genital, en particular vaginosis, vaginitis y vulvovaginitis. Reivindicación 1: Una composición farmacéutica que comprende (i) al menos un éster de glicerina con un ácido graso saturado de C₈₋₁₀, (ii) al menos un éster de glicéridos de polietilenglicol con un ácido graso saturado de C₁₂₋₁₄, y (iii) al menos un éster de polietilenglicol con un ácido graso saturado de C₁₆₋₁₈, y (iv) bencidamina en una cantidad igual o menor que 0.5% p/p con respecto al peso total de la composición farmacéutica, con la condición de que, cuando bencidamina está presente como hidrocloruro de bencidamina en una cantidad de 0.12% p/p, junto con Miglyol 812 en una cantidad de 3% p/p, Tefose 63 en una cantidad de 18% p/p, y Labrafil M2130CS en una cantidad de 3% p/p, dicha composición no comprenda nitrato de econazol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16178742 | 2016-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109254A1 true AR109254A1 (es) | 2018-11-14 |
Family
ID=56408999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101851A AR109254A1 (es) | 2016-07-08 | 2017-07-05 | Composición farmacéutica que comprende bencidamina |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20190224168A1 (es) |
| EP (1) | EP3481370B1 (es) |
| JP (1) | JP7060526B2 (es) |
| KR (1) | KR20190026686A (es) |
| CN (1) | CN109562058A (es) |
| AR (1) | AR109254A1 (es) |
| AU (1) | AU2017294402A1 (es) |
| BR (1) | BR112018077430A2 (es) |
| CA (1) | CA3025863A1 (es) |
| CY (1) | CY1124250T1 (es) |
| DK (1) | DK3481370T3 (es) |
| EA (1) | EA037435B1 (es) |
| ES (1) | ES2877133T3 (es) |
| HR (1) | HRP20210762T1 (es) |
| HU (1) | HUE054775T2 (es) |
| IL (1) | IL264083A (es) |
| LT (1) | LT3481370T (es) |
| MD (1) | MD3481370T2 (es) |
| MX (1) | MX2018015637A (es) |
| PL (1) | PL3481370T3 (es) |
| PT (1) | PT3481370T (es) |
| RS (1) | RS62022B1 (es) |
| SG (1) | SG11201900033UA (es) |
| SI (1) | SI3481370T1 (es) |
| WO (1) | WO2018007288A1 (es) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE109978T1 (de) | 1989-03-31 | 1994-09-15 | Lepetit Spa | Verwendung von purpuromycin zur behandlung von vaginalinfektionen. |
| CA2009402A1 (en) * | 1990-02-06 | 1991-08-06 | Attilio J. De Sanctis | Use of benzydamine and salts thereof for relief of pain associated with herpes viral infections and laser vaporization of condylomata |
| GB9610359D0 (en) | 1996-05-17 | 1996-07-24 | Edko Trading Representation | Pharmaceutical compositions |
| US6913759B2 (en) * | 2003-03-11 | 2005-07-05 | Curatek Pharmaceuticals Holding, Inc. | Gel composition and method for treatment of vaginal infections |
| ITMI20031640A1 (it) * | 2003-08-08 | 2005-02-09 | Mipharm S P A | Base per gel bioadesivi. |
| EP1698336A1 (en) * | 2005-03-01 | 2006-09-06 | Ferrer Internacional, S.A. | Antifungal compositions comprising Sertaconazole and either Hydrocortisone or an antibacterial agent |
| ITBO20050388A1 (it) * | 2005-06-06 | 2006-12-07 | Alfa Wassermann Spa | Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche |
| US20070264309A1 (en) | 2006-01-20 | 2007-11-15 | Chollet Janet A | Method Of Treating Atrophic Vaginitis |
| JP5193196B2 (ja) | 2006-06-02 | 2013-05-08 | ペア ツリー ウーマンズ ヘルス ケア | 萎縮性膣炎の治療の方法 |
| ITMI20071136A1 (it) | 2007-06-04 | 2008-12-05 | Velleja Res Srl | Formulazioni topiche per la prevenzione e il trattamento degli stati infiammatori e/o infettivi dell'aera genitale |
| CN101219139A (zh) * | 2007-12-24 | 2008-07-16 | 广西壮族自治区花红药业股份有限公司 | 盐酸苄达明栓剂及其制备方法 |
| CN101214218A (zh) * | 2007-12-26 | 2008-07-09 | 广西壮族自治区花红药业股份有限公司 | 盐酸苄达明凝胶剂及其制备方法 |
| HUE028220T2 (en) | 2009-07-08 | 2016-12-28 | Acraf | The use of benzidamine in the treatment of p40-dependent diseases |
| WO2013178749A1 (fr) * | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Nanocapsules lipidiques comprenant un rétinoide, nanodispersion et composition les contenant, leur procédé de préparation et leur utilisation en dermatologie |
| US10806697B2 (en) * | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CN107106690B (zh) | 2015-01-13 | 2020-11-10 | 方济各安吉利克化学联合股份有限公司 | 用于治疗真菌病的药物组合物 |
-
2017
- 2017-07-03 DK DK17733862.1T patent/DK3481370T3/da active
- 2017-07-03 CN CN201780041508.8A patent/CN109562058A/zh active Pending
- 2017-07-03 JP JP2018568731A patent/JP7060526B2/ja active Active
- 2017-07-03 EP EP17733862.1A patent/EP3481370B1/en active Active
- 2017-07-03 CA CA3025863A patent/CA3025863A1/en not_active Abandoned
- 2017-07-03 AU AU2017294402A patent/AU2017294402A1/en not_active Abandoned
- 2017-07-03 SG SG11201900033UA patent/SG11201900033UA/en unknown
- 2017-07-03 PT PT177338621T patent/PT3481370T/pt unknown
- 2017-07-03 HU HUE17733862A patent/HUE054775T2/hu unknown
- 2017-07-03 ES ES17733862T patent/ES2877133T3/es active Active
- 2017-07-03 PL PL17733862T patent/PL3481370T3/pl unknown
- 2017-07-03 MD MDE20190569T patent/MD3481370T2/ro unknown
- 2017-07-03 RS RS20210787A patent/RS62022B1/sr unknown
- 2017-07-03 SI SI201730789T patent/SI3481370T1/sl unknown
- 2017-07-03 US US16/314,800 patent/US20190224168A1/en not_active Abandoned
- 2017-07-03 LT LTEP17733862.1T patent/LT3481370T/lt unknown
- 2017-07-03 KR KR1020187037689A patent/KR20190026686A/ko not_active Application Discontinuation
- 2017-07-03 WO PCT/EP2017/066438 patent/WO2018007288A1/en unknown
- 2017-07-03 BR BR112018077430-8A patent/BR112018077430A2/pt not_active IP Right Cessation
- 2017-07-03 MX MX2018015637A patent/MX2018015637A/es unknown
- 2017-07-03 EA EA201990160A patent/EA037435B1/ru unknown
- 2017-07-05 AR ARP170101851A patent/AR109254A1/es unknown
-
2019
- 2019-01-03 IL IL264083A patent/IL264083A/en unknown
-
2021
- 2021-05-12 HR HRP20210762TT patent/HRP20210762T1/hr unknown
- 2021-06-04 CY CY20211100487T patent/CY1124250T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3481370T (pt) | 2021-05-28 |
| EA037435B1 (ru) | 2021-03-26 |
| KR20190026686A (ko) | 2019-03-13 |
| MX2018015637A (es) | 2019-06-17 |
| JP7060526B2 (ja) | 2022-04-26 |
| LT3481370T (lt) | 2021-08-25 |
| EP3481370B1 (en) | 2021-03-24 |
| AU2017294402A1 (en) | 2018-12-20 |
| HRP20210762T1 (hr) | 2021-06-25 |
| IL264083A (en) | 2019-01-31 |
| CA3025863A1 (en) | 2018-01-11 |
| BR112018077430A2 (pt) | 2019-04-02 |
| MD3481370T2 (ro) | 2021-08-31 |
| EA201990160A1 (ru) | 2019-06-28 |
| WO2018007288A1 (en) | 2018-01-11 |
| JP2019520370A (ja) | 2019-07-18 |
| ES2877133T3 (es) | 2021-11-16 |
| PL3481370T3 (pl) | 2021-10-11 |
| CN109562058A (zh) | 2019-04-02 |
| US20190224168A1 (en) | 2019-07-25 |
| SI3481370T1 (sl) | 2021-08-31 |
| RS62022B1 (sr) | 2021-07-30 |
| DK3481370T3 (da) | 2021-06-07 |
| HUE054775T2 (hu) | 2021-09-28 |
| EP3481370A1 (en) | 2019-05-15 |
| SG11201900033UA (en) | 2019-02-27 |
| CY1124250T1 (el) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
| CO2018005361A2 (es) | Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración | |
| CO2018003424A2 (es) | Composición farmacéutica y formulación de inyección subcutánea que comprende micelas y curcuminoides para reducir la grasa localizada y método para preparar la misma” | |
| ECSP14012676A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| CL2013002550A1 (es) | Una formulacion farmaceutica inyectable subcutanea liquida estable altamente concentrada de un anticuerpo anti-her2 farmaceuticamente activo que consiste esencialmente de trastuzumab; his/hci un agente estabilizador y un surfactante no ionico; kit y su uso para tratar enfermedades tales como cancer (divisional de solicitud n°0269-2012). | |
| DOP2013000252A (es) | FORMULACION PARA ANTICUERPO ANTI-a4ß7 | |
| CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| CO2018012258A2 (es) | Compuestos de mic-1 y usos de estos | |
| CL2019002172A1 (es) | Agente terapéutico para enfermedades del hígado. | |
| AR100768A1 (es) | Método para disminuir la inmunogenicidad de proteínas y péptidos | |
| PH12017501571B1 (en) | Topical formulation | |
| CO6731092A2 (es) | Nueva forma de administración de inhibidor de encefalinasa | |
| BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
| WO2013009800A3 (en) | Compositions of alkylating agents and methods of treating skin disorders therewith | |
| MX2022013566A (es) | Anticuerpo. | |
| MX2015003074A (es) | Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas. | |
| CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
| MX2015016410A (es) | Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos. | |
| CL2019001746A1 (es) | Amidas aromáticas de ácido carboxílico | |
| DOP2017000142A (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos | |
| CL2020000221A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| CL2016001130A1 (es) | Composiciones sólidas de triglicéridos y usos de estas | |
| CO2018002428A2 (es) | Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol | |
| AR109254A1 (es) | Composición farmacéutica que comprende bencidamina | |
| PE20140104A1 (es) | Composiciones farmaceuticas que comprenden alisporivir |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |